|07-21-2012, 08:21 AM||#1|
Join Date: Sep 2004
Transplantation of human amniotic mesenchymal stem cells for focal cerebral ischemia
Mol Med Report. 2012 Sep;6(3):625-30. doi: 10.3892/mmr.2012.968. Epub 2012 Jun 26.
Transplantation of human amniotic mesenchymal stem cells in the treatment of focal cerebral ischemia.
Li F, Miao ZN, Xu YY, Zheng SY, Qin MD, Gu YZ, Zhang XG.
Institute of Medical Biotechnology, Soochow University, Jiangsu Province Key Laboratory of Stem Cells, Suzhou 215007, P.R. China.
Cerebrovascular injury is one of the three major causes of death and is the leading cause of adult disability. Despite the increasing progress in emergency treatment and early rehabilitation in patients with cerebrovascular injury, treatment options for neurological dysfunction that presents at a later stage are lacking. This study examined the potential of human amniotic mesenchymal stem cell (hAMSC) transplantation in the repair of neurological deficits in an experimental focal cerebral ischemia model. Following the isolation of hAMSCs, growth characteristics and surface antigen expression were observed. Butylated hydroxyanisole (BHA) was used to induce the cultured cells into neuron-like cells, which were identified by immunocytochemistry. The suture model was used to induce focal cerebral ischemia in rats, which were subsequently randomly divided into experimental and control groups for treatment with BrdU-labeled hAMSCs or PBS, respectively. Neurological deficits were assessed following transplantation using the neurological severity score, beam balance test and elevated body swing test. Eight weeks later, rat brain tissue was analyzed with H&E staining and BrdU immunohistochemistry, and the survival and spatial distribution of the transplanted hAMSCs were determined. The hAMSCs proliferated in vitro, and it was found that neuron-specific enolase (NSE) was expressed in neurons, whereas glial fibrillary acidic protein (GFAP) was expressed in astrocytes. The focal ischemia model caused varying degrees of left limb hemiplegia accompanied by right sided Horner's Syndrome. When examined 1, 3, 6 and 8 weeks later, significant recovery in neurological behavior was detected in the rats treated with hAMSC transplantation compared with the control (P<0.01). BrdU-labeled hAMSCs were concentrated near the graft site and surrounding areas, in certain cases migrating towards the ischemic lesion. Local gliosis and lymphocytic infiltration were not detected. hAMSCs exhibit great potential for proliferation and are induced to differentiate into NSE-expressing neuron-like cells following treatment with BHA. Moreover, hAMSC transplantation may improve neurological symptoms following focal cerebral ischemia.
“As the cast of villains in SCI is vast and collaborative, so too must be the chorus of hero's that rise to meet them” Ramer et al 2005
|Thread||Thread Starter||Forum||Replies||Last Post|
|Transplantation of neuronal-primed human bone marrow mesenchymal stem cells||wildwilly||Neurodegeneration Research||0||06-25-2011 08:51 AM|
|Growth factors improve neurogenesis and outcome after focal cerebral ischemia.||wildwilly||Brain Injury & Stroke Research||0||10-22-2009 04:27 AM|
|Cerebral transplantation of encapsulated mesenchymal stem cells||wildwilly||Brain Injury & Stroke Research||0||08-01-2009 08:59 AM|
|Co-transplantation of bFGF-expressing amniotic epithelial cells and neural stem cells||wildwilly||SCI (Animal) Research||0||11-08-2008 03:04 PM|
|Honma (2005). Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat.||Wise Young||Brain Injury & Stroke Research||0||09-21-2005 02:27 AM|